Clinical research companies IACT Health, LMC Manna Research, and True North Clinical Research have joined forces and announced the formation of the integrated research site organisation (IRO) Centricity Research.
In November last year, IACT Health and LMC Manna Research formed a strategic alliance, and this continued with the integration of True North Clinical Research in December. The mergers have resulted in the largest combined research network in North America, according to a press release.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Centricity Research has over 40 fully owned and integrated clinical research offices in the US and Canada with access to more than 1.6 million patients and over 150 active investigators.
The IRO conducts inpatient and outpatient Phase I-IV clinical research in more than 35 therapeutic areas. These areas include infectious disease, endocrinology, neurology, cardiology, dermatology, oncology, vaccines and women’s health, among others.
IACT LMC Manna Research COO Karri Venn said: “Centricity Research is excited to bring more opportunities for clinical research in terms of geography and therapeutic areas to patients throughout North America.
“Together, we also offer sponsors and CROs multi-site, multi-provincial, and statewide access to clinical research centres and experienced investigators who can perform trials across any therapeutic speciality.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn December last year, IACT LMC Manna Research integrated with True North Clinical Research substantially extending the services of the organisation in central nervous system (CNS) disorders.
A two-site network of CNS-directed clinical research centres, True North was launched in 2006 to carry out clinical research trials in Alzheimer’s dementia.
It now handles broad-ranging trials for CNS disorders, such as mild cognitive impairment, Huntington’s, depression and attention deficit hyperactivity disorder.
In July last year, LMC Manna Research formed a strategic collaboration with Knowde Group to improve the quality and performance of trials in cannabis and psychedelic research.
